• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    1/30/24 4:31:06 PM ET
    $AXDX
    $CELU
    $CNSP
    $GLTO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AXDX alert in real time by email

    Gainers

    • SINTX Techs (NASDAQ:SINT) shares increased by 75.0% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $2.1 million.
    • NuCana (NASDAQ:NCNA) stock rose 10.0% to $0.33. The market value of their outstanding shares is at $17.4 million.
    • CNS Pharma (NASDAQ:CNSP) stock rose 7.39% to $0.25. The company's market cap stands at $1.5 million.
    • OneMedNet (NASDAQ:ONMD) stock moved upwards by 6.66% to $1.6. The company's market cap stands at $51.6 million.
    • Galecto (NASDAQ:GLTO) stock moved upwards by 5.04% to $0.67. The market value of their outstanding shares is at $18.1 million.
    • Accelerate Diagnostics (NASDAQ:AXDX) shares moved upwards by 5.0% to $1.47. The company's market cap stands at $29.7 million.

    Losers

    • Solid Biosciences (NASDAQ:SLDB) shares decreased by 10.3% to $7.25 during Tuesday's after-market session. The market value of their outstanding shares is at $269.3 million.
    • Spruce Biosciences (NASDAQ:SPRB) stock fell 10.22% to $3.08. The market value of their outstanding shares is at $125.3 million.
    • Celularity (NASDAQ:CELU) shares fell 7.88% to $0.31. The market value of their outstanding shares is at $67.1 million.
    • Assure Hldgs (NASDAQ:IONM) stock declined by 7.45% to $0.23. The company's market cap stands at $1.5 million.
    • Petros Pharma (NASDAQ:PTPI) stock decreased by 6.51% to $1.15. The company's market cap stands at $2.5 million.
    • Iterum Therapeutics (NASDAQ:ITRM) shares fell 5.7% to $1.49. The market value of their outstanding shares is at $20.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AXDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXDX
    $CELU
    $CNSP
    $GLTO

    CompanyDatePrice TargetRatingAnalyst
    Solid Biosciences Inc.
    $SLDB
    3/20/2026$26.00Buy
    Guggenheim
    Galecto Inc.
    $GLTO
    2/17/2026$45.00Buy
    UBS
    Galecto Inc.
    $GLTO
    1/7/2026$46.00Outperform
    Leerink Partners
    Spruce Biosciences Inc.
    $SPRB
    12/23/2025$283.00Outperform
    Oppenheimer
    Solid Biosciences Inc.
    $SLDB
    12/4/2025$16.00Buy
    Needham
    Spruce Biosciences Inc.
    $SPRB
    12/3/2025$160.00Market Perform → Outperform
    Leerink Partners
    Galecto Inc.
    $GLTO
    12/1/2025$32.00Buy
    Guggenheim
    Spruce Biosciences Inc.
    $SPRB
    10/28/2025$254.00Mkt Perform → Mkt Outperform
    Citizens JMP
    More analyst ratings

    $AXDX
    $CELU
    $CNSP
    $GLTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI

    MINNEAPOLIS, April 01, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), is pleased to announce that Inka Health, a wholly-owned subsidiary of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has entered into a collaboration with OneMedNet Inc., under which Onco-Innovations and Inka Health will have access to OneMedNet's iRWD™ platform— powered by Palantir (PLTR) Foundry— providing it access to U.S. real-world oncology data. The agreement is intended to accelerate development timelines, reduce clinical and re

    4/1/26 8:55:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Iterum Therapeutics Announces Filing of Winding Up Petition

    DUBLIN and CHICAGO, March 27, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (in Provisional Liquidation) (NASDAQ:ITRM) (the "Company" or "Iterum" or "we"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has filed a petition in the High Court in Ireland to wind up the Company. An Order was made appointing Damien Murran and Jennifer McMahon, each of Teneo Restructuring (Ireland) Limited (the "Joint Provisional Liquidators"), as Joint Provisional Liquidators to the Company. The petition is due to be heard on April 13, 2026. If a winding up

    3/27/26 9:25:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $AXDX
    $CELU
    $CNSP
    $GLTO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $AXDX
    $CELU
    $CNSP
    $GLTO
    SEC Filings

    View All

    SEC Form EFFECT filed by Solid Biosciences Inc.

    EFFECT - Solid Biosciences Inc. (0001707502) (Filer)

    4/1/26 12:15:07 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Solid Biosciences Inc.

    EFFECT - Solid Biosciences Inc. (0001707502) (Filer)

    4/1/26 12:15:05 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form NT 10-K filed by Celularity Inc.

    NT 10-K - Celularity Inc (0001752828) (Filer)

    3/31/26 5:13:34 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXDX
    $CELU
    $CNSP
    $GLTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Solid Biosciences with a new price target

    Guggenheim initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $26.00

    3/20/26 8:37:32 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS initiated coverage on Galecto with a new price target

    UBS initiated coverage of Galecto with a rating of Buy and set a new price target of $45.00

    2/17/26 8:59:23 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Galecto with a new price target

    Leerink Partners initiated coverage of Galecto with a rating of Outperform and set a new price target of $46.00

    1/7/26 8:34:02 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXDX
    $CELU
    $CNSP
    $GLTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Smith Ian F

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    4/2/26 4:05:06 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Levy Elliott M.

    3 - NuCana plc (0001709626) (Issuer)

    4/1/26 4:32:56 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Harrison David James

    3 - NuCana plc (0001709626) (Issuer)

    3/24/26 4:20:53 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXDX
    $CELU
    $CNSP
    $GLTO
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

    Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026 Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company's Commercial Capabilities in Preparation for a Potential Launch of TA-ERT Secured up to $50 Million in Growth Capital from Avenue Capital Group Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate update

    3/9/26 7:05:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXDX
    $CELU
    $CNSP
    $GLTO
    Financials

    Live finance-specific insights

    View All

    Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

    CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (NASDAQ:SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce[1].

    1/18/26 7:02:00 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OneMedNet Reports 815% Bookings Increase and 4.5X increase in Inbound Demand

    MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), announced its financial results for the third quarter ended September 30, 2025 and operational highlights. Third Quarter Financial Highlights Bookings:  $1.1M in third quarter 2025 bookings, an 815% increase compared to third quarter of 2024.Private Placements: Successfully completed an additional $0.5M private placement of common stock from an insider, providing further investment towards strategic objectives.Further Improved Balance Sheet: Continuing with its efforts first reported at the end of the second qu

    11/17/25 7:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Iterum Therapeutics Reports Third Quarter 2025 Financial Results

    --Commercially Launched ORLYNVAH™ in the United States in August 2025-- --Extended Cash Runway into Q2 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended September 30, 2025. "We are thrilled to have launched ORLYNVAH™ in the United States in August 2025 for the treatment of uncomplicated urinary tract infections (uUTIs)," said

    11/14/25 7:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXDX
    $CELU
    $CNSP
    $GLTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13D/A filed by Solid Biosciences Inc.

    SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)

    11/14/24 7:59:25 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Iterum Therapeutics plc

    SC 13G/A - Iterum Therapeutics plc (0001659323) (Subject)

    11/14/24 7:54:21 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care